Literature DB >> 10438394

Antibodies reactive with the cryptococcal capsular polysaccharide glucuronoxylomannan are present in sera from children with and without human immunodeficiency virus infection.

J Abadi1, L a Pirofski.   

Abstract

Antibodies reactive with the cryptococcal polysaccharide glucuronoxylomannan (GXM) are present in sera from both human immunodeficiency virus (HIV)-uninfected and -infected adults. However, the prevalence of these antibodies in US children is unknown. An antigen-capture ELISA was used to determine the presence, serotype specificity, isotype, and IgG subclass distribution of antibodies to GXM in sera from 27 HIV-uninfected and 34 HIV-infected children. The children were of similar age and socioeconomic background. IgG and IgM to GXM were present in sera from all children, although HIV-uninfected children had significantly higher titers. HIV-uninfected children had IgG1 and IgG2 to GXM and significantly greater IgG2 than in HIV-infected children. These findings of type-specific antibodies to GXM in early childhood suggest that exposure to or subclinical infection with Cryptococcus neoformans may be an early childhood event.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10438394     DOI: 10.1086/314953

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  40 in total

1.  Cryptococcal Meningitis in HIV-Infected Patients.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-08       Impact factor: 3.725

Review 2.  Membrane vesicle release in bacteria, eukaryotes, and archaea: a conserved yet underappreciated aspect of microbial life.

Authors:  Brooke L Deatherage; Brad T Cookson
Journal:  Infect Immun       Date:  2012-03-12       Impact factor: 3.441

3.  Antibody immunity and natural resistance to cryptococcosis.

Authors:  N Trevijano-Contador; L Pirofski
Journal:  Curr Trop Med Rep       Date:  2019-04-04

4.  Human immunoglobulin G2 (IgG2) and IgG4, but not IgG1 or IgG3, protect mice against Cryptococcus neoformans infection.

Authors:  David O Beenhouwer; Esther M Yoo; Chun-Wei Lai; Miguel A Rocha; Sherie L Morrison
Journal:  Infect Immun       Date:  2007-01-12       Impact factor: 3.441

5.  In vivo role of dendritic cells in a murine model of pulmonary cryptococcosis.

Authors:  Karen L Wozniak; Jatin M Vyas; Stuart M Levitz
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

Review 6.  Cryptococcal interactions with the host immune system.

Authors:  Kerstin Voelz; Robin C May
Journal:  Eukaryot Cell       Date:  2010-04-09

7.  Immunogenicity and efficacy of Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan peptide mimotope-protein conjugates in human immunoglobulin transgenic mice.

Authors:  Robert W Maitta; Kausik Datta; Andrew Lees; Shelley Sims Belouski; Liise-anne Pirofski
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

8.  Enhanced innate immune responsiveness to pulmonary Cryptococcus neoformans infection is associated with resistance to progressive infection.

Authors:  Loïc Guillot; Scott F Carroll; Robert Homer; Salman T Qureshi
Journal:  Infect Immun       Date:  2008-08-04       Impact factor: 3.441

Review 9.  Cryptococcal Disease in HIV-Infected Children.

Authors:  Carol Kao; David L Goldman
Journal:  Curr Infect Dis Rep       Date:  2016-09       Impact factor: 3.725

10.  Protective and nonprotective human immunoglobulin M monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan manifest different specificities and gene use profiles.

Authors:  Robert W Maitta; Kausik Datta; Qing Chang; Robin X Luo; Bradley Witover; Krishanthi Subramaniam; Liise-anne Pirofski
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.